Recent Updates
Recently added Catalysts
REGN

Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO

Thursday, September 3, 2020 1 min read
Key Takeaway: Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO

Full Press Release Details

Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO.
Tags: REGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 3, 2020